ELVN-002 is an investigational medication being studied for its potential to treat advanced stage HER2 positive solid tumors. In this trial, it is being tested in combination with other treatments to evaluate its safety and how well it is tolerated by patients. The goal is to find the best dose to use when combined with other therapies.

Trastuzumab is a medication used to treat certain types of cancer that are HER2 positive. It works by targeting and blocking the HER2 protein, which can help slow down or stop the growth of cancer cells. In this trial, trastuzumab is combined with ELVN-002 and other chemotherapy treatments to assess its effectiveness in treating advanced stage HER2 positive cancers.

CAPEOX is a chemotherapy regimen that includes capecitabine and oxaliplatin. It is used to treat colorectal cancer by interfering with the growth of cancer cells. In this study, CAPEOX is combined with ELVN-002 and trastuzumab to evaluate its safety and effectiveness in patients with advanced stage HER2 positive colorectal cancer.

mFOLFOX6 is another chemotherapy regimen that includes 5-fluorouracil, leucovorin, and oxaliplatin. It is used to treat colorectal cancer by targeting cancer cells and preventing them from growing. This trial combines mFOLFOX6 with ELVN-002 and trastuzumab to study its impact on advanced stage HER2 positive colorectal cancer.

Eribulin is a chemotherapy drug used to treat breast cancer. It works by stopping cancer cells from dividing and growing. In this trial, eribulin is combined with ELVN-002 and trastuzumab to explore its safety and effectiveness in patients with advanced stage HER2 positive breast cancer.

Capecitabine is a chemotherapy medication that is used to treat various types of cancer, including breast cancer. It is taken orally and works by interfering with the DNA of cancer cells, preventing them from growing. In this study, capecitabine is used alongside ELVN-002 and trastuzumab to assess its role in treating advanced stage HER2 positive breast cancer.

Paclitaxel is a chemotherapy drug used to treat breast cancer. It works by stopping cancer cells from dividing, which can help slow or stop the growth of the cancer. In this trial, paclitaxel is combined with ELVN-002 and trastuzumab to evaluate its safety and effectiveness in patients with advanced stage HER2 positive breast cancer.

Solid Tumors – Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. They can occur in various parts of the body and are classified based on the type of cells they originate from. These tumors can grow and spread to other parts of the body, a process known as metastasis. The progression of solid tumors depends on their location, size, and the specific type of cells involved. They can cause symptoms by pressing on nearby organs or tissues.

Colorectal Cancer – Colorectal cancer begins in the colon or rectum, parts of the digestive system. It often starts as small, benign clumps of cells called polyps, which can become cancerous over time. As the cancer progresses, it can invade the walls of the colon or rectum and spread to nearby lymph nodes or other organs. Symptoms may include changes in bowel habits, blood in the stool, and abdominal discomfort. The progression of the disease can vary based on factors like the cancer’s stage and location.

Breast Cancer – Breast cancer originates in the cells of the breast, often in the ducts or lobules. It can spread to nearby lymph nodes and other parts of the body. The disease progresses through stages, from localized tumors to more advanced stages where cancer cells have spread. Symptoms may include a lump in the breast, changes in breast shape, or skin changes. The rate of progression can vary depending on the type and characteristics of the cancer cells.